Skip to main content

Table 1 Characteristics of the A1ATD and usual COPD cohorts

From: Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD

Variable A1ATD cohort (n = 540) Usual COPD cohort (n = 316) p
Age 53.9 (45.0–60.9) 68.8 (61.5–75.1) <0.001
Sex Male n = 311 (57.6 %) Male n = 182 (57.6 %) 0.999
Female n = 229 (42.4 %) Female n = 134 (42.4 %)
Pack years 11.6 (0.0–24.0) 44.1 (29.5–62.2) <0.001
FEV1 (% predicted) 50.7 (35.1–85.1) 46.4 (35.0–61.0) <0.001
KCO (% predicted) 62.3 (49.3–77.0) 59 (47.5–77.0) 0.533
Chronic bronchitis 185 (34.3 %) 198 (62.7 %) <0.001
Emphysema 358 (66.3 %) 257 (81.3 %) 0.002
Bronchiectasis 142 (26.3 %) 96 (30.3 %) 0.678
Frequent exacerbator 129 (40.8 %) 193 (61.1 %) <0.001
eGFR 81.3 (70.6–93.9) 85.8 (69.7–101.1) 0.063
CKD stage    0.002
1 eGFR ≥ 90 156 (28.9 %) 119 (37.6 %)
2 eGFR 60–89 279 (51.7 %) 130 (41.1 %)
3 eGFR 30–59 41 (7.6 %) 35 (11.1 %)
4 eGFR 15–29 2 (0.4 %) 4 (1.3 %)
5 eGFR < 15 1 (0.2 %) 0 (0 %)
Unknown (no eGFR) 61 (11.3 %) 28 (8.9 %)
cFLC (mg/L) 25.7 (21.1–31.7) 31.9 (24.0–43.3) <0.001
κ/λ 0.86 (0.71–1.08) 0.86 (0.72–1.06) 0.967
  1. Number of patients with contemporaneous renal function = 479 A1ATD, 288 usual COPD. Continuous variables expressed as median (IQR); sex, chronic bronchitis, emphysema, bronchiectasis, exacerbators and CKD stage expressed as number in each group (%). A frequent exacerbator was defined as having 2 or more exacerbations per year. BMI body mass index, FEV1 forced expiratory volume in 1 s, KCO corrected gas transfer, eGFR estimated glomerular filtration rate, cFLC combined (κ + λ) free light chain level (mg/L)
  2. P values highlighted in bold indicate significant differences between the A1ATD and Usual COPD cohorts (p ≤ 0.05)